Travere Therapeutics Inc. (TVTX)
NASDAQ: TVTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
TVTX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $4.51B
- Forward P/E
- 8.68
- EPS (TTM)
- -$1.67
- Dividend yield
- None
- 52-week range
- 22.59 – 68.73
- Day range
- 46.90 – 49.29
- Volume / Avg
- 1.33M / 1.81M
- Beta
- —
- Shares outstanding
- 95.99M
52-week range
TVTX stock today
On Nov 20, TVTX ended the session at $47.00, shedding $1.30 (2.69%), versus the S&P 500's 3.70% decline. At this level, TVTX sits in the middle of its 52-week range of $22.59 to $68.73: 31.6% below the high, set on Sep 11, 2026 and 108.1% above the low. TVTX is up 23.0% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 35.5%.
Travere Therapeutics has posted a net loss over the last twelve months (EPS of -$1.67), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Travere Therapeutics
Company profileTravere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Eric M. Dube Ph.D.
- Headquarters
- San Diego, CA
- Employees
- 497
- Website
- travere.com
Financial highlights
Full financialsIn fiscal 2025, Travere Therapeutics generated $490.7 million in revenue, up 110.5% from fiscal 2024, its 3rd consecutive year of revenue growth. Travere Therapeutics reported a net loss of $25.5 million, compared with a loss of $321.5 million a year earlier. Gross margin was 97.9% (up from 96.7%) and operating margin -12.8%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $490.73M | $233.18M | $145.24M | $109.46M | $131.84M |
| Growth | +110.45% | +60.55% | +32.69% | -16.97% | -33.52% |
| Net income | $-25.55M | $-321.55M | $-111.40M | $-278.48M | $-180.09M |
| EPS (diluted) | $-0.29 | $-4.08 | $-1.50 | $-4.37 | $-3.01 |
Analyst forecast
ForecastConsensus (15 analysts)
strong_buy
Avg. price target
$73.43+56.23%
- Strong buy 2
- Buy 12
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 2, 2026
- EPS actual vs est.
- $0.28 vs $-0.25
- Surprise
- +212.00%
TVTX news
All TVTX news- Why is Travere Therapeutics stock sliding today?Investing.com
- Travere (TVTX) Q3 2026 Earnings Call TranscriptNasdaq
- Travere Therapeutics Non-GAAP EPS of -$0.31 misses by $0.73, revenue of $224.5M beats by $29.21MSeeking Alpha
- Travere Therapeutics Reports Third Quarter 2026 Financial ResultsBusiness Wire
- Travere Therapeutics Q3 2026 Earnings PreviewSeeking Alpha
- Travere Therapeutics to Report Third Quarter 2026 Financial ResultsBusiness Wire
- AstraZeneca Gets Accelerated FDA Nod for Ultomiris in IgA NephropathyNasdaqAZN, NVS, TVTX
- Biotech Stocks At 52-Week Highs - TXG, OBIO, AVAH, OSCR, LFST, TVTXNasdaqAVAH, LFST, OBIO, OSCR
Travere Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| IONSIonis Pharmaceuticals Inc. | 26.58 | -2.35% | $4.43B | vs TVTX |
| COGTCogent Biosciences Inc. | 26.72 | -3.69% | $4.65B | vs TVTX |
| EWTXEdgewise Therapeutics Inc. | 39.91 | -3.07% | $4.37B | vs TVTX |
| PTCTPTC Therapeutics Inc. | 56.42 | -3.27% | $4.71B | vs TVTX |
| DNTHDianthus Therapeutics Inc. | 84.55 | -0.33% | $4.76B | vs TVTX |
| ERASErasca Inc. | 13.61 | -4.29% | $4.78B | vs TVTX |
| LQDALiquidia Corporation | 54.43 | -3.88% | $4.90B | vs TVTX |
| MANEVeradermics Incorporated | 119.52 | -3.92% | $5.04B | vs TVTX |
Indexes, lists and sector
Travere Therapeutics stock FAQ
What is Travere Therapeutics's stock price today?
TVTX last traded at $47.00 as of Nov 20, 4:00 PM EST, down 2.69% on the day. Prices are delayed at least 15 minutes.
Who is Travere Therapeutics's CEO?
Dr. Eric M. Dube Ph.D. is the chief executive officer of Travere Therapeutics Inc., which has about 497 employees.
What is the TVTX 52-week high?
The 52-week high for TVTX is $68.73 and the 52-week low is $22.59. The stock is currently 31.6% below its high.